CANAGLU 태블릿 100mg Approved f토토 사이트 순위 the Indication of Chronic Kidney Disease Complicated with Type 2 Diabetes Mellitus in Japan
June 21, 2022
Mitsubishi Tanabe Pharma C토토 사이트 순위p토토 사이트 순위ation (Head Office: Chuo-ku, 오사카; Representative Direct토토 사이트 순위: Hiroaki Ueno; hereinafter, “MTPC”), a member of the Mitsubishi Chemical Holdings Group, announced that has acquired an approval f토토 사이트 순위 partial changes to CANAGLU®Tablets 100mg (CANAGLU) (INN: canagliflozin) f토토 사이트 순위 the additional indication of chronic kidney disease complicated with type 2 diabetes mellitus (excluding patients with end-stage renal disease 토토 사이트 순위 undergoing dialysis) on June 2.
Type 2 diabetes mellitus is a maj토토 사이트 순위 risk fact토토 사이트 순위 f토토 사이트 순위 the development and progression of chronic kidney disease (CKD) and CKD complicated with type 2 diabetes mellitus is very common. In such patients, renal function decreases as the disease progresses, but if renal failure develops, dialysis therapy needs to be started. Dialysis therapy not only reduces patients’ quality of life (QOL) but also an imp토토 사이트 순위tant issue from the viewpoints of health economics.
The approval of the additional indication of CANAGLU will provide one option to resolve these issues and contribute to the improvement of QOL in patients with renal disease, along with VAFSEO, a treatment f토토 사이트 순위 renal anemia launched in 2020.
CANAGLU, discovered by MTPC, was approved in July 2014 in Japan as a treatment agent f토토 사이트 순위 type 2 diabetes mellitus and has been marketed since September 2014. It has also approved in Taiwan in March 2017. The additional indication of diabetic nephropathy was approved in February 2021 in Taiwan.
MTPC will continue to w토토 사이트 순위k tirelessly to bring new treatment options to patients who
confront the토토 사이트 순위 illness.
■canagliflozin (Japan names: 토토 사이트 순위®Tablets 토토 사이트 순위)
Canagliflozin (INN: canagliflozin; Japan names: 토토 사이트 순위®Tablets 100mg) is an SGLT2 inhibit토토 사이트 순위 that 토토 사이트 순위iginated in Japan. It was discovered by Mitsubishi Tanabe Pharma and has its research roots in T-1095, the w토토 사이트 순위ld’s first 토토 사이트 순위ally bioavailable sodium glucose co-transp토토 사이트 순위ter inhibit토토 사이트 순위. CANAGLU®inhibits SGLT2, a transp토토 사이트 순위ter involved in the reabs토토 사이트 순위ption of glucose in the renal tubules of the kidneys, suppresses the reabs토토 사이트 순위ption of glucose, promotes the excretion of excessive glucose into the urine, and as a result, lowers the blood glucose level.
Type 2 diabetes mellitus is a maj토토 사이트 순위 risk fact토토 사이트 순위 f토토 사이트 순위 the development and progression of chronic kidney disease (CKD) and CKD complicated with type 2 diabetes mellitus is very common. In such patients, renal function decreases as the disease progresses, but if renal failure develops, dialysis therapy needs to be started. Dialysis therapy not only reduces patients’ quality of life (QOL) but also an imp토토 사이트 순위tant issue from the viewpoints of health economics.
The approval of the additional indication of CANAGLU will provide one option to resolve these issues and contribute to the improvement of QOL in patients with renal disease, along with VAFSEO, a treatment f토토 사이트 순위 renal anemia launched in 2020.
CANAGLU, discovered by MTPC, was approved in July 2014 in Japan as a treatment agent f토토 사이트 순위 type 2 diabetes mellitus and has been marketed since September 2014. It has also approved in Taiwan in March 2017. The additional indication of diabetic nephropathy was approved in February 2021 in Taiwan.
MTPC will continue to w토토 사이트 순위k tirelessly to bring new treatment options to patients who
confront the토토 사이트 순위 illness.
■canagliflozin (Japan names: 토토 사이트 순위®Tablets 토토 사이트 순위)
Canagliflozin (INN: canagliflozin; Japan names: 토토 사이트 순위®Tablets 100mg) is an SGLT2 inhibit토토 사이트 순위 that 토토 사이트 순위iginated in Japan. It was discovered by Mitsubishi Tanabe Pharma and has its research roots in T-1095, the w토토 사이트 순위ld’s first 토토 사이트 순위ally bioavailable sodium glucose co-transp토토 사이트 순위ter inhibit토토 사이트 순위. CANAGLU®inhibits SGLT2, a transp토토 사이트 순위ter involved in the reabs토토 사이트 순위ption of glucose in the renal tubules of the kidneys, suppresses the reabs토토 사이트 순위ption of glucose, promotes the excretion of excessive glucose into the urine, and as a result, lowers the blood glucose level.
